Friday, November 6, 2020
- 9:00AM-11:00AM
-
Abstract Number: 0286
An SLE-linked ITGAM Gene Variant Changes Mac-1 Structure, Signaling, and Surface Expression and Enhances IFNg Production and Antigen Presentation by B Cells
SLE – Etiology & Pathogenesis Poster- 9:00AM-11:00AM
-
Abstract Number: 0079
Analysis of COVID-19 and Rheumatology Twitter Activity During the Pandemic Months
Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing- 9:00AM-11:00AM
-
Abstract Number: 0131
Analysis of the Total Body Composition in a Cohort of Patients with Elderly Onset Arthritis
Osteoporosis & Metabolic Bone Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 0281
ANCA in SLE: Prevalence and Predictor Factors
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations- 9:00AM-11:00AM
-
Abstract Number: 0060
ANCA-associated Vasculitis in Caucasian and Hispanics of the Inland Empire of Southern California
Healthcare Disparities in Rheumatology Poster- 9:00AM-11:00AM
-
Abstract Number: 0424
Anti-Collagen II Antibodies in Patients with Relapsing Polychondritis
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I- 9:00AM-11:00AM
-
Abstract Number: 0007
Antimalarial Drug Shortages During the COVID-19 Pandemic: Results from the Global Rheumatology Alliance Patient Experience Survey
Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease- 9:00AM-11:00AM
-
Abstract Number: 0010
Antirheumatic Disease Therapies in Patients with COVID-19: A Systematic Review and Meta-analysis
Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease- 9:00AM-11:00AM
-
Abstract Number: 0336
Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis- 9:00AM-11:00AM
-
Abstract Number: 0257
Application of Text Mining Methods to Identify Lupus Nephritis from Electronic Health Records
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations- 9:00AM-11:00AM
-
Abstract Number: 0124
Appropriate Timing of Denosumab Dosing and Subsequent Therapy After Discontinuation: An Academic Medical Center Experience
Osteoporosis & Metabolic Bone Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 0123
Aromatase Inhibitor-Associated Bone Loss: Screening and Prevention
Osteoporosis & Metabolic Bone Disease Poster- 9:00AM-11:00AM
-
Abstract Number: 0397
Assessing Adherence to Screening of Systemic Sclerosis-Related Lung Disease